Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton therapy in adjuvant pancreatic cancer
NCT03885284Phase 1Completed
- Sponsor
- Georgetown University
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Georgetown University. Primary endpoints: Dose Limiting Toxicities at 6 months, Adverse Events at 6 months and 1 more. Started Jul 2019; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03885284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03885284.